These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8915508)

  • 1. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
    Ramezani A; Joshi S
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1.
    Ramezani A; Ma XZ; Nazari R; Joshi S
    Front Biosci; 2002 Feb; 7():a29-36. PubMed ID: 11815297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
    Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
    Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme.
    Weerasinghe M; Liem SE; Asad S; Read SE; Joshi S
    J Virol; 1991 Oct; 65(10):5531-4. PubMed ID: 1895402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
    Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
    Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
    Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization of an anti-tat ribozyme for therapeutic application.
    Wang L; Witherington C; King A; Gerlach WL; Carr A; Penny R; Cooper D; Symonds G; Sun LQ
    Hum Gene Ther; 1998 Jun; 9(9):1283-91. PubMed ID: 9650613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA.
    Lo KM; Biasolo MA; Dehni G; Palú G; Haseltine WA
    Virology; 1992 Sep; 190(1):176-83. PubMed ID: 1529527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
    Liem SE; Ramezani A; Li X; Joshi S
    Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid.
    Ohkawa J; Yuyama N; Taira K
    Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HIV-1 replication by an anti-tat hammerhead ribozyme.
    Jackson WH; Moscoso H; Nechtman JF; Galileo DS; Garver FA; Lanclos KD
    Biochem Biophys Res Commun; 1998 Apr; 245(1):81-4. PubMed ID: 9535787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s).
    Cohli H; Fan B; Joshi RL; Ramezani A; Li X; Joshi S
    Antisense Res Dev; 1994; 4(1):19-26. PubMed ID: 7914762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.